Deregulation of FOXF1/FENDRR from t(14;16)(q32;q24) defines a subtype of high risk lineage ambiguous leukemia
Despite great progress in understanding the genomic basis of immature T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL) and acute leukemias of ambiguous lineage (ALAL), there are still cases that lack defining genetic markers, complicating risk stratification and limiting targeted therapeutic options. Here, we describe a subtype of leukemia defined by the t(14;16)(q32;q24) translocation, which places the FOXF1 gene and its antisense long noncoding RNA gene FENDRR under the regulatory control of the BCL11B enhancer, leading to their ectopic transcriptional activation. Analysis of different high-throughput sequencing data, including WGS, RNA-seq, scDNA-seq, scRNA-seq, ChIP-seq, ATAC-seq, and HiChIP-seq, identified BCL11B-enhancer mediated deregulation of FOXF1/FENDRR as a hallmark of a subtype of high-risk lineage ambiguous leukemia that is potentially amenable to targeted therapeutic intervention.
- Type: Cancer Genomics
- Archiver: European Genome-phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD50000001786 | Illumina NovaSeq X | 10 | |
| EGAD50000001787 | Illumina NovaSeq X | 2 | |
| EGAD50000001788 | Illumina NovaSeq X | 3 | |
| EGAD50000001789 | Illumina NovaSeq X | 8 | |
| EGAD50000001790 | Illumina NovaSeq X | 21 | |
| EGAD50000001791 | Illumina NovaSeq X | 2 | |
| EGAD50000001792 | Illumina NovaSeq X | 3 | |
| EGAD50000001793 | Illumina NovaSeq X | 2 |
